2024
The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users. Contraception 2024, 140: 110539. PMID: 39002624, PMCID: PMC11588555, DOI: 10.1016/j.contraception.2024.110539.Peer-Reviewed Original ResearchContraceptive implant usersSerum etonogestrel concentrationsEtonogestrel concentrationsImplant usersEtonogestrel implant usersSteady-state pharmacokineticsLifestyle factorsIncreased caloric intakeInfluence of lifestyle factorsCaloric intakeSubstance useCross-sectional analysisEtonogestrelCurrent dietInconsistent associationsExercise habitsAssociationDietPharmacokineticsExerciseSerumSurvey responsesIntake
2021
An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users. The European Journal Of Contraception & Reproductive Health Care 2021, 26: 323-325. PMID: 33596152, PMCID: PMC8496990, DOI: 10.1080/13625187.2021.1887475.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsExercise habitsImplant usersStanford Brief Activity SurveySteady-state pharmacokineticsReproductive-age womenLiquid chromatography-mass spectrometry assayEtonogestrel implantsLifestyle factorsSedentary lifestyleMass spectrometry assaySecondary analysisSignificant associationVital signsActivity SurveyDietAssociationExploratory studyInconsistent effectsHabitsParticipantsPharmacokineticsSurvey responses
2011
Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone
Bruce RD, Moody DE, Fang WB, Chodkowski D, Andrews L, Friedland GH. Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone. The American Journal Of Drug And Alcohol Abuse 2011, 37: 224-228. PMID: 21438849, DOI: 10.3109/00952990.2011.568081.Peer-Reviewed Original ResearchConceptsTPV/rSteady-state pharmacokinetic evaluationGlucuronide metabolitesBUP/naloxoneHIV-negative subjectsHIV-seronegative subjectsBuprenorphine/naloxoneSteady-state pharmacokineticsCytochrome P450 3A4Ritonavir effectsPharmacodynamic consequencesPharmacokinetic evaluationBuprenorphineNorBUPCombined inhibitionNaloxoneCurve AUCP450 3A4AUCSignificant increasePharmacokineticsTipranavirPrevious reportsSubjectsMetabolites
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply